View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 28, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 29,600,000
Entity Common Stock, Shares Outstanding		59,236,369
Trading Symbol	STXS
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 10,796,072	$ 3,686,302
Accounts receivable, net of allowance of $398,847 and $361,350 in 2018 and 2017, respectively	5,021,111	4,287,255
Inventories, net	1,191,666	1,146,971
Prepaid expenses and other current assets	963,700	750,085
Total current assets	17,972,549	9,870,613
Property and equipment, net	343,693	592,688
Intangible assets, net		159,470
Other assets	198,365	44,432
Total assets	18,514,607	10,667,203
Current liabilities:
Accounts payable	1,726,360	1,654,101
Accrued liabilities	2,642,481	3,195,247
Deferred revenue	5,825,536	5,702,769
Warrants		19,574,977
Total current liabilities	10,194,377	30,127,094
Long-term deferred revenue	407,151	611,863
Other liabilities	641,461	535,369
Total liabilities	11,242,989	31,274,326
Convertible Preferred stock:
Convertible Preferred stock, par value $0.001; 10,000,000 shares authorized, 23,900 shares outstanding at 2018 and 2017	5,960,475	5,960,475
Stockholders' equity (deficit):
Common stock, par value $0.001; 300,000,000 shares authorized, 59,058,297 and 22,805,731 shares issued at 2018 and 2017, respectively	59,058	22,806
Additional paid in capital	478,179,574	450,748,403
Treasury stock, 4,015 shares at 2018 and 2017	(205,999)	(205,999)
Accumulated deficit	(476,721,490)	(477,132,808)
Total stockholders' equity (deficit)	1,311,143	(26,567,598)
Total liabilities and stockholders' equity (deficit)	$ 18,514,607	$ 10,667,203

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 398,847	$ 361,350
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	23,900	23,900
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	59,058,297	22,805,731
Treasury stock, shares	4,015	4,015

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Systems	$ 1,582,053	$ 4,275,798
Disposables, service and accessories	27,764,564	26,868,302
Total revenue	29,346,617	31,144,100
Cost of revenue:
Systems	1,788,658	6,199,643
Disposables, service and accessories	3,928,521	4,554,596
Total cost of revenue	5,717,179	10,754,239
Gross margin	23,629,438	20,389,861
Operating expenses:
Research and development	8,219,387	6,704,200
Sales and marketing	12,965,920	13,627,724
General and administrative	4,901,170	5,977,534
Total operating expenses	26,086,477	26,309,458
Operating loss	(2,457,039)	(5,919,597)
Other income	2,590,361	212,031
Interest income (expense)	(16,566)	(179,844)
Net income (loss)	116,756	(5,887,410)
Cumulative dividend on convertible preferred stock	(1,434,000)	(1,432,259)
Net loss attributable to common stockholders	$ (1,317,244)	$ (7,319,669)
Net loss per share attributable to common stockholders:
Basic	$ (0.03)	$ (0.32)
Diluted	$ (0.03)	$ (0.32)
Weighted average number of common shares and equivalents:
Basic	52,082,618	22,614,248
Diluted	52,082,618	22,614,248

Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)

Convertible Preferred Stock [Member]

Common Stock [Member]

Additional Paid-In Capital [Member]

Treasury Stock [Member]

Accumulated Deficit [Member]

Total

Beginning Balance at Dec. 31, 2016

$ 5,960,475

$ 22,064

$ 449,939,406

$ (205,999)

$ (471,245,398)

$ (21,489,927)

Beginning Balance, Shares at Dec. 31, 2016

23,900

22,063,582

Share-based compensation

768,682

Restricted stock vesting

$ 675

(552)

123

Restricted stock vesting, Shares

675,473

Components of comprehensive Income (loss): net Income (loss)

(5,887,410)

Employee stock purchase plan

$ 67

40,867

40,934

Employee stock purchase plan, Shares

66,676

Ending Balance at Dec. 31, 2017

$ 5,960,475

$ 22,806

450,748,403

(205,999)

(477,132,808)

(26,567,598)

Ending Balance, Shares at Dec. 31, 2017

23,900

22,805,731

Share-based compensation

561,115

Restricted stock vesting

$ 294

(294)

Restricted stock vesting, Shares

293,912

Components of comprehensive Income (loss): net Income (loss)

116,756

Employee stock purchase plan

$ 74

56,917

56,991

Employee stock purchase plan, Shares

74,367

Issuance of common stock and warrants

$ 35,793

26,813,524

26,849,317

Issuance of common stock and warrants, Shares

35,792,593

Grant of restricted shares, net of forfeitures

$ 91

(91)

Grant of restricted shares, net of forfeitures, Shares

91,694

Cumulative Catchup for Adoption of ASC 606

^[1]

294,562

Ending Balance at Dec. 31, 2018

$ 5,960,475

$ 59,058

$ 478,179,574

$ (205,999)

$ (476,721,490)

$ 1,311,143

Ending Balance, Shares at Dec. 31, 2018

23,900

59,058,297

[1]	Represents the adjustments related to the adoption of new accounting standards. See Note 2 for details.

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net income (loss)	$ 116,756	$ (5,887,410)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	513,029	554,361
Amortization of intangibles	65,988	199,321
Amortization of deferred finance costs	24,657	99,998
Share-based compensation	560,973	768,682
Loss on asset disposal	94,931	98,550
Adjustment of warrants	(2,590,361)	(212,030)
Provisions for obsolete inventory	320,447	3,948,726
Changes in operating assets and liabilities:
Accounts receivable	(733,856)	378,704
Inventories	(365,142)	285,406
Prepaid expenses and other current assets	(124,419)	105,215
Other assets	26,775	(5,191)
Accounts payable	72,259	(968,909)
Accrued liabilities	(552,766)	(1,295,917)
Deferred revenue	(81,945)	(2,959,033)
Other liabilities	106,092	214,960
Net cash used in operating activities	(2,546,582)	(4,674,567)
Cash flows from investing activities
Purchase of fixed assets	(265,482)	(81,577)
Net cash used in investing activities	(265,482)	(81,577)
Cash flows from financing activities
Payments of deferred financing costs		(100,000)
Proceeds from issuance of stock, net of issuance costs	57,137	41,054
Proceeds from warrant exercise	9,864,697
Net cash provided by (used in) financing activities	9,921,834	(58,946)
Net increase (decrease) in cash and cash equivalents	7,109,770	(4,815,090)
Cash and cash equivalents at beginning of period	3,686,302	8,501,392
Cash and cash equivalents at end of period	10,796,072	3,686,302
Supplemental disclosures of cash flow information:
Interest paid

Description of Business

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

1. Description of Business

Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”), and related devices.

The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter resulting in improved navigation, efficient procedures and reduced x-ray exposure. As of December 31, 2018, the Company had an installed base of 126 Niobe ES systems.

In addition to the robotic magnetic system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training.

Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the robotic magnetic system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems.

We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure and equipment service costs beyond warranty period. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.

The core components of Stereotaxis systems, such as Niobe system, Odyssey Solution, Cardiodrive and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and Europe. The V-CAS Deflect catheter advancement system has been CE Marked for sale in Europe.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company believes the cash on hand at December 31, 2018 will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. The Company has sustained operating losses throughout its corporate history and expects that its 2019 expenses will exceed its 2019 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of robotic magnetic systems and placement of new robotic magnetic systems as well as by new placements of capital systems. The Company also may consider raising cash through capital transactions, which could include either debt or equity financing.

Cash and Cash Equivalents

The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2018 or 2017.

Accounts Receivable and Allowance for Uncollectible Accounts

Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.

Financial Instruments

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value.

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for disclosure of fair value measurements.

Inventory

The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.

Property and Equipment

Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.

Long-Lived Assets

If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.

Intangible Assets

Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.

Revenue and Costs of Revenue

Revenue Recognition

The Company adopted Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”), Revenue from Contracts with Customers, on January 1, 2018 using the modified retrospective method. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) applying the modified retrospective method only to open contracts as of December 31, 2017; (ii) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (iii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; and (iv) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

Upon adoption of the new revenue guidance, the Company recorded a cumulative-effect reduction to accumulated deficit of $0.3 million on January 1, 2018 relating primarily to the deferral of previously expensed costs to obtain a contract. The Company capitalized sales commissions paid in connection with multi-year service contracts and is amortizing such asset over the economic life of those contracts. Previously, sales commissions on multi-year service contracts were expensed as incurred. The impact of this change on operating expenses in any given period will depend, in part, on the amount of such commissions incurred and capitalized in relation to the amount of ongoing amortization expense. For the twelve months ended December 31, 2018, the Company recorded no material impact to commission expense as a result of adopting the new standard. The Company did not otherwise experience significant changes in the timing or method of revenue recognition for any of its material revenue streams.

We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from other recurring revenue including ongoing software and service contracts.

We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities.

For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates as necessary.

Systems:

Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from system delivery and installation represented 5% and 13% of revenue for the twelve months ended December 31, 2018 and 2017, respectively.

Disposables:

Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 33% of revenue for the twelve months ended December 31, 2018 and 2017, respectively.

Royalty:

The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 10% of revenue for the twelve months ended December 31, 2018 and 2017.

Other Recurring Revenue:

Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for one year following installation. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 52% and 44% of revenue for the twelve months ended December 31, 2018 and 2017, respectively.

	Twelve Months Ended December 31,
	2018		2017
Systems	$	1,582,053	$	4,275,798
Disposables, service and accessories		27,764,564		26,868,302
Total revenue	$	29,346,617	$	31,144,100

Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company's systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $2.8 million as of December 31, 2018. Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract.

The following information summarizes the Company’s contract assets and liabilities:

	December 31, 2018			December 31, 2017
Contract Assets - Unbilled Receivables	$	251,867		$	2,917

Customer deposits		487,086			—
Product shipped, revenue deferred		645,199			941,724
Deferred service and license fees		5,100,402			5,372,908
Total deferred revenue		6,232,687			6,314,632
Less: Long-term deferred revenue		(407,151	)		(611,863	)
Total current deferred revenue	$	5,825,536		$	5,702,769

The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented.

Revenue recognized for the twelve months ended December 31, 2018 and 2017, that was included in the deferred revenue balance at the beginning of each reporting period was $5.5 million and $8.0 million, respectively.

The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets, in the Company’s balance sheet was $0.3 million as of December 31, 2018. The Company did not incur any impairment losses during any of the periods presented.

Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.

Research and Development Costs

Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2018 or 2017 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.

Share-Based Compensation

Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date.

The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years.

Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.

Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory.

Net Earnings (Loss) per Common Share

Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive.

The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses.

As of December 31, 2018, the Company had 1,165,086 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $2.54 per share, 1,131,151 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.70 per share, and 41,743,654 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2018.

Income Taxes

In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.

Product Warranty Provisions

The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.

Patent Costs

Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.

Concentrations of Risk

The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits.

Revenue from Biosense Webster Inc. related to royalties and Odyssey system sales accounted for $2.9 million and $3.3 million, or 10% and 11%, of total net revenue for the years ended December 31, 2018, and 2017, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2018. No single country other than the U.S. accounted for more than 10% of total revenue for the years ended December 31, 2018 and 2017.

Reclassifications

In 2018, we adjusted our operating expense categories to improve our alignment with common industry reporting practice, and as a result, certain amounts in prior periods have been reclassified to conform to the current period presentation. For the year ended December 31, 2017, approximately $1.9 million of regulatory and clinical research expenses previously included in General and Administrative expense have been reclassified to Research and Development expense, and approximately $0.6 million of international training expense previously included in General and Administrative expense has been reclassified to Sales and Marketing expense. These reclassifications had no effect on reported income or losses.

Recently Issued Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2016-02 (“ASU 2016-02”), Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is substantially complete with our evaluation of the impact of adopting ASU 2016-02 on its consolidated financial statements and will adopt ASU 2016-02 during the first quarter of 2019 using the alternative modified transition method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is recognized on the date of adoption with prior periods not restated.

The new standard provides a number of optional practical expedients in transition. The Company expects to elect the ‘package of practical expedients’, which permits it not to reassess under the new standard its prior conclusions about lease identification, lease classification, and initial direct costs. In addition, the new standard provides practical expedients for an entity’s ongoing accounting that the Company anticipates making, such as the (1) the election for certain classes of underlying asset to not separate non-lease components from lease components and (2) the election for short-term lease recognition exemption for all leases that qualify.

As a lessee, the Company believes the largest impact will be on its consolidated balance sheets for the accounting of facilities-related leases, which represents the majority of the operating leases it has entered into as a lessee. These leases will be recognized under the new standard as Right of Use (“ROU”) assets and operating lease liabilities. The Company will also be required to provide expanded disclosures for its leasing arrangements. As of December 31, 2018, the Company had between $6.0 million and $7.0 million of undiscounted future minimum operating lease commitments that are not recognized on its consolidated balance sheets as determined under the current standard. For a lessee, the results of operations are not expected to significantly change after adoption of the new standard.

In addition, from time to time, the Company has sublet a portion of its operating facilities. Under the existing standard, the Company recorded any sub-lease proceeds as a reduction to its operating expenses. Under the new standard, as a lessor, the Company will record these amounts as Other Income. The Company does not expect this change to have a material impact on its consolidated financial statements.

While substantially complete, the Company is still finalizing its adoption of ASC 842 and the related impact on the Company’s financial statements and disclosures. As the Company completes its evaluation of this new standard during the first quarter of 2019, new information may arise that could change the Company’s current assessment of the impact to existing accounting. Additionally, the Company will continue to monitor industry activities and any additional guidance provided by regulators, standards setters, or the accounting profession, and adjust the Company’s assessment and implementation plans accordingly.

Inventory

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventory

3. Inventory

Inventory consists of the following:

	December 31, 2018			December 31, 2017

Raw materials	$	2,686,870		$	2,528,270
Work in process		2,594			4,836
Finished goods		2,963,013			2,515,637
Reserve for obsolescence		(4,460,811	)		(3,901,772	)
Total inventory	$	1,191,666		$	1,146,971

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2018

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	December 31, 2018			December 31, 2017

Prepaid expenses	$	401,972		$	575,501
Prepaid commissions		304,585			-
Deferred financing costs		-			24,658
Deposits		455,508			194,358
Total prepaid expenses and other assets		1,162,065			794,517
Less: Noncurrent prepaid expenses and other assets		(198,365	)		(44,432	)
Total current prepaid expenses and other assets	$	963,700		$	750,085

Property and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

5. Property and Equipment

Property and equipment consist of the following:

	December 31, 2018			December 31, 2017

Equipment	$	6,831,665		$	7,295,698
Leasehold improvements		2,592,339			2,592,339
		9,424,004			9,888,037
Less: Accumulated depreciation		(9,080,311	)		(9,295,349	)
Net property and equipment	$	343,693		$	592,688

Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

6. Intangible Assets

As of December 31, 2018 and 2017, the Company had total intangible assets of $3,049,810 and $3,143,291, respectively. Accumulated amortization at December 31, 2018 and 2017 was $3,049,810 and $2,983,821, respectively. Amortization expense for 2018 and 2017 was $65,988 and $199,321, respectively, as determined under the straight-line method. For the twelve months ended December 31, 2018 and 2017, the Company also recognized impairment charges of $93,482 and $77,778, respectively in research and development expense related to certain intellectual property rights. The impairment is the result of an analysis that indicated it was probable the undiscounted cash flows derived from the intellectual property would not exceed its book value during its remaining useful life.

Accrued Liabilities

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:

	December 31, 2018			December 31, 2017

Accrued salaries, bonus, and benefits	$	1,491,844		$	1,641,491
Accrued rent		69,826			441,417
Accrued licenses and maintenance fees		576,598			581,672
Accrued warranties		149,464			164,365
Accrued taxes		251,988			234,668
Accrued professional services		430,088			367,072
Other		314,134			299,931
Total accrued liabilities		3,283,942			3,730,616
Less: Long term accrued liabilities		(641,461	)		(535,369	)
Total current accrued liabilities	$	2,642,481		$	3,195,247

Long-Term Debt and Credit Facilities

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Long-Term Debt and Credit Facilities

8. Long-Term Debt and Credit Facilities

As of December 31, 2018 and 2017, there were no contractual principal maturities of debt.

The revolving line of credit is secured by substantially all of the Company’s assets. The Company is required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

Revolving line of credit

The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $5.0 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender.

On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to April 25, 2019. The maximum availability under the revolving line of credit remains at $5.0 million, and provides for an interest rate during a “streamline period” equal to the prime rate subject to a floor of 4.5%. A “streamline period” occurs when the Company has, for each consecutive day in the immediately preceding monthly period, maintained a liquidity ratio greater than 1.75:1.00, and continuing so long as the streamline period has been maintained. Upon the termination of a streamline period, the Company must maintain the streamline threshold each consecutive day for one fiscal quarter, prior to entering into a subsequent streamline period. During non-streamline periods, the interest rate is the prime rate plus 1.5%, subject to a floor of 4.5%. In addition, the amendment requires that the liquidity ratio shall at all times include not less than $1.5 million of the Borrower’s unrestricted cash and cash equivalents maintained at the Bank prior to giving effect to any advance.

As of December 31, 2018, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of December 31, 2018 the Company had a borrowing capacity of $3.3 million based on the Company’s collateralized assets. The Company’s total liquidity as of December 31, 2018, was $14.1 million, which included cash and cash equivalents of $10.8 million. As of December 31, 2018, we were in compliance with all financial covenants of this agreement and we anticipate continued compliance throughout the remainder of 2019.

Lease Obligations

12 Months Ended

Dec. 31, 2018

Leases [Abstract]

Lease Obligations

9. Lease Obligations

The Company leases its facilities under operating leases. For the years ended December 31, 2018 and 2017 rent expense was $718,736 and $588,197, respectively. The rent expense for the years ended December 31, 2018 and 2017 is net of sublease income of $837,949 and $812,660, respectively.

The lease for the Company’s principal executive office space and manufacturing facilities expired on December 31, 2018. On January 10, 2019, the company exercised its remaining renewal option to extend the term of the lease by three years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.

The future minimum lease payments under non-cancelable leases as of December 31, 2018 are as follows (excluding any potential sublease income):

Year	Operating Lease Payments
2019	$	2,334,382
2020		2,364,408
2021		2,404,565
Total minimum lease payments		7,103,355

Convertible Preferred Stock and Stockholders' Equity

12 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Convertible Preferred Stock and Stockholders' Equity

10. Convertible Preferred Stock and Stockholders’ Equity

The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2018.

Convertible Preferred Stock and Warrants

In September 2016, the Company issued 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock at an initial conversion rate of $0.65 per share and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent (6%) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets, or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a defined change of control. The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution, and winding up of the Company. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet.

The warrants issued in conjunction with the convertible preferred stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. Prior to their modification in February 2018, the warrants were puttable upon the occurrence of certain events outside of the Company’s control, and were classified as liabilities under ASC 480-10. The calculated fair value of the warrants was periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. See Note 11 for additional details.

The warrants were modified on February 28, 2018 to allow for a reduction in the exercise price from $0.70 per share to $0.28 per share for a period between March 1, 2018 and March 5, 2018. Additionally, the beneficial ownership limitation related to the warrants was modified and the right of holders to require the Company to redeem their SPA Warrants in exchange for cash in certain circumstances was eliminated. Following these modifications, the warrants were no longer subject to liability accounting and were reclassified to equity. During the restricted exercise period, Stereotaxis received exercise notices for 35,791,927 warrants and received an aggregate of $10.0 million in cash from the warrant exercise. As a result of these transactions, total stockholders’ equity increased by $27.0 million and common shares outstanding increased by 35,791,927 shares.

The Company has reserved shares of common stock for conversion of convertible preferred stock, exercise of warrants, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:

	December 31, 2018		December 31, 2017
Warrants		1,131,151		38,779,119
Series A Convertible Preferred Stock Series		47,844,562		47,844,562
Stock award plans		4,438,503		5,573,046
Employee Stock Purchase Plan		51,251		125,618
		53,465,467		92,322,345

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.

The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.

Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors.

Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of equity awards to new directors generally vest over a two year period. Annual grants to directors generally vest between one and five years following grant.

A summary of the option and stock appreciation rights activity for the year ended December 31, 2018 is as follows:

	Number of Options/SARs			Range of Exercise Price		Weighted Average Exercise Price per Share

Outstanding, December 31, 2017		413,301		$	0.62 - $54.90	$	9.04
Granted		950,500		$	0.74 - $1.07	$	0.76
Exercised		(2,916	)	$	0.62	$	0.62
Forfeited		(195,799	)	$	0.62 - $54.90	$	7.66
Outstanding, December 31, 2018		1,165,086		$	0.74 - $43.90	$	2.54

As of December 31, 2018, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 8.18 years. Of the 1,165,086 options and stock appreciation rights that were outstanding as of December 31, 2018, 291,679 were vested and exercisable with a weighted average exercise price of $7.83 per share and a weighted average remaining term of 5.16 years.

A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:

	Year Ended December 31, 2018
Range of Exercise Prices	Options Outstanding		Weighted Average Remaining Life		Weighted Average Exercise Price		Number of Options Currently Exercisable		Weighted Average Exercise Price Per Vested Share

$0.00 - $1.00		818,500		9.18	$	0.75		-	$	-
$1.01 - $2.00		101,500		7.86	$	1.48		51,718	$	1.86
$2.01- $4.00		115,791		6.11	$	2.15		110,666	$	2.15
$4.01 - $10.00		86,500		5.24	$	4.04		86,500	$	4.04
$10.01 - $20.00		-		-	$	-		-	$	0.00
$30.01 - $40.00		30,545		1.92	$	34.74		30,545	$	34.74
$40.01 - $50.00		12,250		0.44	$	43.90		12,250	$	43.90
		1,165,086		8.18	$	2.54		291,679	$	7.83

The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money at December 31, 2018. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2018 was approximately $0.3 million based on a closing share price of $1.08 on December 31, 2018. There were no fully vested options or stock appreciation rights outstanding at December 31, 2018 with an exercise price less than the closing stock price on December 31, 2018. During the year ended December 31, 2018 the aggregate intrinsic value of options and stock appreciation rights exercised under the Company’s stock option plans was less than $0.1 million. No options or stock appreciation rights were exercised under the Company’s stock option plans during the year-ended December 31, 2017, and the Company realized no proceeds during that period. The weighted average grant date fair value of options and stock appreciation rights granted during the year ended December 31, 2018 was $0.76 per share.

A summary of the restricted stock unit activity for the year ended December 31, 2018 is as follows:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2017		680,363		$	1.11
Granted		422,167		$	0.80
Vested		(385,606	)	$	1.24
Forfeited		(69,275	)	$	1.12
Outstanding, December 31, 2018		647,649		$	0.83

The intrinsic value of restricted stock units outstanding at December 31, 2018 was $0.7 million based on a closing share price of $1.08 as of December 31, 2018. During the year ended December 31, 2018, the aggregate intrinsic value of restricted stock units vested was $0.3 million determined at the date of vesting.

As of December 31, 2018, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $0.6 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods.

2009 Employee Stock Purchase Plan

In 2009, the Company adopted its 2009 Employee Stock Purchase Plan (“ESPP”). In June 2014, our shareholders approved an amendment of the ESPP to increase the number of shares authorized for issuance under the ESPP by 250,000 shares. Eligible employees have the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees can purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. As of December 31, 2018, there were 51,251 remaining shares available for issuance under the Employee Stock Purchase Plan.

Fair Value Measurements

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

11. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

	Level 1:	Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

	Level 2:	Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

	Level 3:	Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities at December 31, 2018
Warrants issued August 2013	$	—	$	—	$	—	$	—
Warrants issued September 2016		—		—		—		—
Total liabilities at fair value:	$	—	$	—	$	—	$	—
Liabilities at December 31, 2017:
Warrants issued August 2013	$	5,746	$	—	$	—	$	5,746
Warrants issued September 2016		19,569,231		—		—		19,569,231
Total liabilities at fair value:	$	19,574,977	$	—	$	—	$	19,574,977

Level 1

The Company does not have any financial assets or liabilities classified as Level 1.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with the Company’s August 2013 and September 2016 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements at the time of issuance, the warrants did not meet the exemptions for equity classification and as such, the Company accounted for these warrants as derivative instruments. The calculated fair value of the warrants issued in conjunction with the August 2013 financing transactions was classified as a liability and periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations until their expiration in November 2018. As detailed in Note 10, the remaining warrants from the September 2016 transaction were modified on February 28, 2018 and reclassified to equity.

The remaining warrants from the August 2013 transaction (Exchange Warrants) expired November 2018 and were last revalued as of September 30, 2018 using the following assumptions: 1) volatility of 70.17%; 2) risk-free interest rate of 2.19%; and 3) a closing stock price of $1.21.

Using the same option pricing model, the Exchange warrants were valued as of December 31, 2017 using the following assumptions: 1) volatility of 70.56%; 2) risk-free interest rate of 1.76%; and 3) a closing stock price of $0.80.

The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) liability fair value measurement.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the year ended December 31, 2018:

	Warrants issued August 2013			Warrants issued September 2016			Total Liabilities
Balance at beginning of period	$	5,746		$	19,569,231		$	19,574,977
Issues		-			-			-
Settlements		-			(16,984,616	)		(16,984,616	)
Revaluation		(5,746	)		(2,584,615	)		(2,590,361	)
Balance at end of period	$	-		$	-		$	-

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

12. Income Taxes

The provision for income taxes consists of the following:

	Year Ended December 31,
	2018			2017
Deferred:
Federal	$	(236,779	)	$	13,308,196
State and local		(238,946	)		(263,860	)
		(475,725	)		13,044,336
Valuation allowance		475,725			(13,044,336	)
	$	—		$	—

The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:

	Year Ended December 31,
	2018			2017
U.S. statutory income tax rate		21.0	%		34.0	%
State and local taxes, net of federal tax benefit		(42.8	)%		1.8	%
Permanent differences between book and tax		(390.5	)%		(1.5	)%
Deferred tax adjustments		293.5	%		(6.1	)%
Tax cuts & jobs act		0.0	%		(244.9	)%
State rate adjustments		(292.9	)%		(4.0	)%
Prior year return-to-provision adjustment		4.3	%		0.0	%
Valuation allowance		407.4	%		220.7	%
Effective income tax rate		—	%		—	%

Included in permanent differences between book and tax in the above table are the impacts of the non-deductible mark-to-market activity associated with convertible debt and warrants as well as permanent differences such as nondeductible meals and entertainment and stock compensation shortfalls. The deferred state rate adjustments are a result of changes in apportionment and various state rate law changes. The deferred tax adjustments are primarily attributable to the write-off of deferred tax assets associated with the unexercised stock compensation awards that expired during the current year.

The components of the deferred tax asset are as follows:

	December 31,
	2018			2017
Current accruals	$	1,746,094		$	1,718,808
Deferred revenue		605			30,648
Depreciation and amortization		1,279,973			1,311,718
Deferred compensation		471,143			633,303
Net operating loss carryovers		22,933,668			22,359,693
Deferred tax assets		26,431,483			26,054,170
Valuation allowance		(26,359,083	)		(25,955,759	)
Capitalized compensation costs		(72,400	)		—
Net deferred tax assets before deferred tax liabilities		—			98,411
Accounting method changes		—			(98,411	)
Net deferred tax assets	$	—		$	—

On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted, which made significant changes to the Internal Revenue Code (“IRC” or “Code”). The TCJA lowered the U.S. federal income tax rate to 21%, beginning on January 1, 2018. Additionally, among other changes, the TCJA imposes a one-time transition tax on the mandatory repatriation of unremitted foreign earnings, as well as a minimum tax on global intangible low-taxed income (“GILTI”) of foreign subsidiaries. As required by SEC Staff Accounting Bulletin 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act, we finalized our accounting analysis with the filing of our 2017 tax returns. We have recorded the impacts of the TCJA in our effective tax rate and have elected to treat taxes due on future U.S. inclusions in taxable income related to GILTI using the period cost method. The Company will continue to monitor the forthcoming regulations and additional guidance of the GILTI, FDII, and BEAT provisions under the TCJA, which are complex and subject to continuing regulatory interpretation by the IRS.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that a large portion of the Company’s net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations as reflected in the net operating loss carryovers in the table above. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets.

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate.

As of December 31, 2018, we had gross federal net operating loss carryforwards of approximately $100.3 million. The federal net operating loss carryforwards reflect accumulated book losses reduced for the 2013 IRC Section 382 ownership change limitation of $284.7 million and approximately $92.0 million of book/tax differences and expiration of unused carryforwards. The federal net operating loss carryforwards generated prior to the 2018 tax year will expire between 2030 and 2037. The federal net operating loss generated during 2018 will be carried forward indefinitely as a result to changes in the law following TCJA. As of December 31, 2018, we had state net operating loss deferred tax assets of approximately $1.9 million which will expire at various dates between 2018 and 2037 if not utilized.

As a result of stock issuances which occurred during the year, the Company believes that an ownership change may have occurred under Section 382 of the Code. Any change could significantly limit the value of the existing net operating loss carryforward. The Company is currently evaluating the impact of the warrant exercise on the availability of its U.S. net operating loss carryforward. Refer to Note 10 for a full discussion of the Company’s equity transactions.

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 1998 forward, all tax years from 1998 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less.

At December 31, 2018 and 2017, the Company had less than $0.1 million in reserves for uncertain tax positions. The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2018, accrued interest and penalties were less than $0.1 million.

Net Loss Per Share

12 Months Ended

Dec. 31, 2018

Net loss per share attributable to common stockholders:

Net Loss Per Share

13. Net Loss per Share

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:

	Twelve months ended December 31,
	2018			2017
Net income (loss)	$	116,756		$	(5,887,410	)
Deemed dividend on convertible preferred stock		—			—
Cumulative dividend on convertible preferred stock		(1,434,000	)		(1,432,259	)
Net loss attributable to common stockholders	$	(1,317,244	)	$	(7,319,669	)

Weighted average number of common shares and equivalents:		52,082,618			22,614,248
Basic EPS	$	(0.03	)	$	(0.32	)
Diluted EPS	$	(0.03	)	$	(0.32	)

The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:

	December 31,
	2018		2017
Shares issuable upon vesting/exercise of:
Options to purchase common stock		1,165,086		413,301
Series A Convertible Preferred Stock and Accumulated Dividends		41,743,654		39,537,501
Restricted stock units		647,649		680,363
Warrants		1,131,151		38,779,119
		44,687,540		79,410,284

Employee Benefit Plan

12 Months Ended

Dec. 31, 2018

Defined Benefit Plan [Abstract]

Employee Benefit Plan

14. Employee Benefit Plan

The Company offers employees the opportunity to participate in a 401(k) plan. For 2018, the Company recognized expense of approximately $0.2 million to match employee contributions up to 3% of each participating employee’s salary. The Company did not match employee contributions made in 2017.

Product Warranty Provisions

12 Months Ended

Dec. 31, 2018

Product Warranties Disclosures [Abstract]

Product Warranty Provisions

15. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe, Odyssey and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:

	December 31, 2018			December 31, 2017
Warranty accrual, beginning of the fiscal period	$	164,365		$	222,845
Accrual adjustment for product warranty		34,253			32,679
Payments made		(49,154	)		(91,159	)
Warranty accrual, end of the fiscal period	$	149,464		$	164,365

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

16. Commitments and Contingencies

The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information

17. Segment Information

The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2018 and 2017 were as follows:

	Year Ended December 31,
	2018		2017
United States	$	18,611,676	$	18,038,638
International		10,734,941		13,105,462
Total	$	29,346,617	$	31,144,100

All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Cash and Cash Equivalents

Cash and Cash Equivalents

Accounts Receivable and Allowance for Uncollectible Accounts

Accounts Receivable and Allowance for Uncollectible Accounts

Financial Instruments

Financial Instruments

Inventory

Inventory

Property and Equipment

Property and Equipment

Long-Lived Assets

Long-Lived Assets

Intangible Assets

Intangible Assets

Use of Estimates

Use of Estimates

Revenue and Costs of Revenue

Revenue and Costs of Revenue

Revenue Recognition

Systems:

Disposables:

Royalty:

Other Recurring Revenue:

	Twelve Months Ended December 31,
	2018		2017
Systems	$	1,582,053	$	4,275,798
Disposables, service and accessories		27,764,564		26,868,302
Total revenue	$	29,346,617	$	31,144,100

The following information summarizes the Company’s contract assets and liabilities:

	December 31, 2018			December 31, 2017
Contract Assets - Unbilled Receivables	$	251,867		$	2,917

Customer deposits		487,086			—
Product shipped, revenue deferred		645,199			941,724
Deferred service and license fees		5,100,402			5,372,908
Total deferred revenue		6,232,687			6,314,632
Less: Long-term deferred revenue		(407,151	)		(611,863	)
Total current deferred revenue	$	5,825,536		$	5,702,769

Research and Development Costs

Research and Development Costs

Share-based Compensation

Share-Based Compensation

Net Earnings (Loss) Per Common Share

Net Earnings (Loss) per Common Share

Income Taxes

Income Taxes

Product Warranty Provisions

Product Warranty Provisions

Patent Costs

Patent Costs

Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.

Concentrations of Risk

Concentrations of Risk

Reclassifications

Reclassifications

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Revenue Disaggregated by Type

	Twelve Months Ended December 31,
	2018		2017
Systems	$	1,582,053	$	4,275,798
Disposables, service and accessories		27,764,564		26,868,302
Total revenue	$	29,346,617	$	31,144,100

Summary of Contract Assets and Liabilities

The following information summarizes the Company’s contract assets and liabilities:

	December 31, 2018			December 31, 2017
Contract Assets - Unbilled Receivables	$	251,867		$	2,917

Customer deposits		487,086			—
Product shipped, revenue deferred		645,199			941,724
Deferred service and license fees		5,100,402			5,372,908
Total deferred revenue		6,232,687			6,314,632
Less: Long-term deferred revenue		(407,151	)		(611,863	)
Total current deferred revenue	$	5,825,536		$	5,702,769

Inventory (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventory consists of the following:

	December 31, 2018			December 31, 2017

Raw materials	$	2,686,870		$	2,528,270
Work in process		2,594			4,836
Finished goods		2,963,013			2,515,637
Reserve for obsolescence		(4,460,811	)		(3,901,772	)
Total inventory	$	1,191,666		$	1,146,971

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2018

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	December 31, 2018			December 31, 2017

Prepaid expenses	$	401,972		$	575,501
Prepaid commissions		304,585			-
Deferred financing costs		-			24,658
Deposits		455,508			194,358
Total prepaid expenses and other assets		1,162,065			794,517
Less: Noncurrent prepaid expenses and other assets		(198,365	)		(44,432	)
Total current prepaid expenses and other assets	$	963,700		$	750,085

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consist of the following:

	December 31, 2018			December 31, 2017

Equipment	$	6,831,665		$	7,295,698
Leasehold improvements		2,592,339			2,592,339
		9,424,004			9,888,037
Less: Accumulated depreciation		(9,080,311	)		(9,295,349	)
Net property and equipment	$	343,693		$	592,688

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consist of the following:

	December 31, 2018			December 31, 2017

Accrued salaries, bonus, and benefits	$	1,491,844		$	1,641,491
Accrued rent		69,826			441,417
Accrued licenses and maintenance fees		576,598			581,672
Accrued warranties		149,464			164,365
Accrued taxes		251,988			234,668
Accrued professional services		430,088			367,072
Other		314,134			299,931
Total accrued liabilities		3,283,942			3,730,616
Less: Long term accrued liabilities		(641,461	)		(535,369	)
Total current accrued liabilities	$	2,642,481		$	3,195,247

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2018

Leases [Abstract]

Schedule of Future Minimum Lease Payments

The future minimum lease payments under non-cancelable leases as of December 31, 2018 are as follows (excluding any potential sublease income):

Year	Operating Lease Payments
2019	$	2,334,382
2020		2,364,408
2021		2,404,565
Total minimum lease payments		7,103,355

Convertible Preferred Stock and Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Summary of Reserved Shares of Common Stock

	December 31, 2018		December 31, 2017
Warrants		1,131,151		38,779,119
Series A Convertible Preferred Stock Series		47,844,562		47,844,562
Stock award plans		4,438,503		5,573,046
Employee Stock Purchase Plan		51,251		125,618
		53,465,467		92,322,345

Summary of Option and Stock Appreciation Rights Activity

A summary of the option and stock appreciation rights activity for the year ended December 31, 2018 is as follows:

	Number of Options/SARs			Range of Exercise Price		Weighted Average Exercise Price per Share

Outstanding, December 31, 2017		413,301		$	0.62 - $54.90	$	9.04
Granted		950,500		$	0.74 - $1.07	$	0.76
Exercised		(2,916	)	$	0.62	$	0.62
Forfeited		(195,799	)	$	0.62 - $54.90	$	7.66
Outstanding, December 31, 2018		1,165,086		$	0.74 - $43.90	$	2.54

Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price

A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:

	Year Ended December 31, 2018
Range of Exercise Prices	Options Outstanding		Weighted Average Remaining Life		Weighted Average Exercise Price		Number of Options Currently Exercisable		Weighted Average Exercise Price Per Vested Share

$0.00 - $1.00		818,500		9.18	$	0.75		-	$	-
$1.01 - $2.00		101,500		7.86	$	1.48		51,718	$	1.86
$2.01- $4.00		115,791		6.11	$	2.15		110,666	$	2.15
$4.01 - $10.00		86,500		5.24	$	4.04		86,500	$	4.04
$10.01 - $20.00		-		-	$	-		-	$	0.00
$30.01 - $40.00		30,545		1.92	$	34.74		30,545	$	34.74
$40.01 - $50.00		12,250		0.44	$	43.90		12,250	$	43.90
		1,165,086		8.18	$	2.54		291,679	$	7.83

Summary of Restricted Stock Unit Activity

A summary of the restricted stock unit activity for the year ended December 31, 2018 is as follows:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2017		680,363		$	1.11
Granted		422,167		$	0.80
Vested		(385,606	)	$	1.24
Forfeited		(69,275	)	$	1.12
Outstanding, December 31, 2018		647,649		$	0.83

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis by Level

	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities at December 31, 2018
Warrants issued August 2013	$	—	$	—	$	—	$	—
Warrants issued September 2016		—		—		—		—
Total liabilities at fair value:	$	—	$	—	$	—	$	—
Liabilities at December 31, 2017:
Warrants issued August 2013	$	5,746	$	—	$	—	$	5,746
Warrants issued September 2016		19,569,231		—		—		19,569,231
Total liabilities at fair value:	$	19,574,977	$	—	$	—	$	19,574,977

Summary of Changes in Fair Value of Level 3 Financial Liabilities

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the year ended December 31, 2018:

	Warrants issued August 2013			Warrants issued September 2016			Total Liabilities
Balance at beginning of period	$	5,746		$	19,569,231		$	19,574,977
Issues		-			-			-
Settlements		-			(16,984,616	)		(16,984,616	)
Revaluation		(5,746	)		(2,584,615	)		(2,590,361	)
Balance at end of period	$	-		$	-		$	-

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Provision For Income Taxes

The provision for income taxes consists of the following:

	Year Ended December 31,
	2018			2017
Deferred:
Federal	$	(236,779	)	$	13,308,196
State and local		(238,946	)		(263,860	)
		(475,725	)		13,044,336
Valuation allowance		475,725			(13,044,336	)
	$	—		$	—

Schedule of Reconciliation of Federal Income Tax Rate

The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:

	Year Ended December 31,
	2018			2017
U.S. statutory income tax rate		21.0	%		34.0	%
State and local taxes, net of federal tax benefit		(42.8	)%		1.8	%
Permanent differences between book and tax		(390.5	)%		(1.5	)%
Deferred tax adjustments		293.5	%		(6.1	)%
Tax cuts & jobs act		0.0	%		(244.9	)%
State rate adjustments		(292.9	)%		(4.0	)%
Prior year return-to-provision adjustment		4.3	%		0.0	%
Valuation allowance		407.4	%		220.7	%
Effective income tax rate		—	%		—	%

Schedule of Components of Deferred Tax Asset

The components of the deferred tax asset are as follows:

	December 31,
	2018			2017
Current accruals	$	1,746,094		$	1,718,808
Deferred revenue		605			30,648
Depreciation and amortization		1,279,973			1,311,718
Deferred compensation		471,143			633,303
Net operating loss carryovers		22,933,668			22,359,693
Deferred tax assets		26,431,483			26,054,170
Valuation allowance		(26,359,083	)		(25,955,759	)
Capitalized compensation costs		(72,400	)		—
Net deferred tax assets before deferred tax liabilities		—			98,411
Accounting method changes		—			(98,411	)
Net deferred tax assets	$	—		$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2018

Net loss per share attributable to common stockholders:

Schedule of Computation of Basic and Diluted Earnings Per Share

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:

	Twelve months ended December 31,
	2018			2017
Net income (loss)	$	116,756		$	(5,887,410	)
Deemed dividend on convertible preferred stock		—			—
Cumulative dividend on convertible preferred stock		(1,434,000	)		(1,432,259	)
Net loss attributable to common stockholders	$	(1,317,244	)	$	(7,319,669	)

Weighted average number of common shares and equivalents:		52,082,618			22,614,248
Basic EPS	$	(0.03	)	$	(0.32	)
Diluted EPS	$	(0.03	)	$	(0.32	)

Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share

The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:

	December 31,
	2018		2017
Shares issuable upon vesting/exercise of:
Options to purchase common stock		1,165,086		413,301
Series A Convertible Preferred Stock and Accumulated Dividends		41,743,654		39,537,501
Restricted stock units		647,649		680,363
Warrants		1,131,151		38,779,119
		44,687,540		79,410,284

Product Warranty Provisions (Tables)

12 Months Ended

Dec. 31, 2018

Product Warranties Disclosures [Abstract]

Schedule of Accrued Warranty

Accrued warranty, which is included in other accrued liabilities, consists of the following:

	December 31, 2018			December 31, 2017
Warranty accrual, beginning of the fiscal period	$	164,365		$	222,845
Accrual adjustment for product warranty		34,253			32,679
Payments made		(49,154	)		(91,159	)
Warranty accrual, end of the fiscal period	$	149,464		$	164,365

Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Schedule of Geographic Revenues

Geographic revenues for the years ended December 31, 2018 and 2017 were as follows:

	Year Ended December 31,
	2018		2017
United States	$	18,611,676	$	18,038,638
International		10,734,941		13,105,462
Total	$	29,346,617	$	31,144,100

Description of Business (Details Narrative)	Dec. 31, 2018 Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Installed base	126

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Mar. 05, 2018	Jan. 02, 2018
Restricted cash
Effect on accumulated deficit				$ 300,000
Effect on income
Deferred revenue, amortization period	1 year
Remaining performance obligation	$ 2,800,000
Revenue recognized	5,500,000	8,000,000
Capitalized contract acquisition costs	300,000
Research and development receivables
Options and stock appreciation rights	1,165,086	413,301
Weighted average exercise price	$ 2.54	$ 9.04
Exercise price of warrants	$ 0.70
Revenues	$ 29,346,617	$ 31,144,100
Future minimum operating lease commitments	$ 7,103,355
Research and Development Expense [Member]
Reclassification amount		1,900,000
Selling and Marketing Expense [Member]
Reclassification amount		$ 600,000
Stock Option [Member]
Options and stock appreciation rights	1,165,086
Weighted average exercise price	$ 2.54
Warrant [Member]
Common stock issuable upon exercise, warrants	1,131,151
Exercise price of warrants	$ 0.70
Series A Convertible Preferred Stock [Member]
Options and stock appreciation rights	41,743,654
Restricted Stock Units [Member]
Unvested restricted shares
Revenue from System Delivery and Installation [Member]
Revenues percentage	5.00%	13.00%
Disposable Revenue [Member]
Revenues percentage	33.00%	33.00%
Royalty Revenue [Member]
Revenues percentage	10.00%	10.00%
Other Recurring Revenue [Member]
Revenues percentage	52.00%	44.00%
Sales Revenue [Member] \| Country Other Than U.S. [Member]
Revenues percentage	10.00%
Sales Revenue [Member] \| Biosense Webster Inc [Member] \| Customer Concentration Risk [Member]
Revenues percentage	10.00%	11.00%
Revenues	$ 2,900,000	$ 3,300,000
Sales Revenue [Member] \| Customer [Member] \| Customer Concentration Risk [Member]
Revenues percentage	10.00%
Minimum [Member]
Property and equipment, estimated useful lives	3 years
Intangible assets, estimated useful lives	10 years
Share-based compensation, requisite service period	1 year
Exercise price of warrants			$ 0.28
Future minimum operating lease commitments	$ 6,000,000
Maximum [Member]
Property and equipment, estimated useful lives	10 years
Intangible assets, estimated useful lives	15 years
Share-based compensation, requisite service period	4 years
Exercise price of warrants			$ 0.70
Future minimum operating lease commitments	$ 7,000,000

Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Type (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total revenue	$ 29,346,617	$ 31,144,100
Systems [Member]
Total revenue	1,582,053	4,275,798
Disposables, Service and Accessories [Member]
Total revenue	$ 27,764,564	$ 26,868,302

Summary of Significant Accounting Policies - Summary of Contract Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Total deferred revenue	$ 6,232,687	$ 6,314,632
Less: Long-term deferred revenue	(407,151)	(611,863)
Total current deferred revenue	5,825,536	5,702,769
Contract Assets - Unbilled Receivables [Member]
Total deferred revenue	251,867	2,917
Customer Deposits [Member]
Total deferred revenue	487,086
Product Shipped, Revenue Deferred [Member]
Total deferred revenue	645,199	941,724
Deferred Service and License Fees [Member]
Total deferred revenue	$ 5,100,402	$ 5,372,908

Inventory - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 2,686,870	$ 2,528,270
Work in process	2,594	4,836
Finished goods	2,963,013	2,515,637
Reserve for obsolescence	(4,460,811)	(3,901,772)
Total inventory	$ 1,191,666	$ 1,146,971

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 401,972	$ 575,501
Prepaid commissions	304,585
Deferred financing costs		24,658
Deposits	455,508	194,358
Total prepaid expenses and other assets	1,162,065	794,517
Less: Noncurrent prepaid expenses and other assets	(198,365)	(44,432)
Total current prepaid expenses and other assets	$ 963,700	$ 750,085

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Gross property and equipment	$ 9,424,004	$ 9,888,037
Less: Accumulated depreciation	(9,080,311)	(9,295,349)
Net property and equipment	343,693	592,688
Equipment [Member]
Gross property and equipment	6,831,665	7,295,698
Leasehold Improvements [Member]
Gross property and equipment	$ 2,592,339	$ 2,592,339

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Total intangible assets	$ 3,049,810	$ 3,143,291
Accumulated amortization	3,049,810	2,983,821
Amortization expense	65,988	199,321
Impairment charges	$ 93,482	$ 77,778

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued salaries, bonus, and benefits	$ 1,491,844	$ 1,641,491
Accrued rent	69,826	441,417
Accrued licenses and maintenance fees	576,598	581,672
Accrued warranties	149,464	164,365	$ 222,845
Accrued taxes	251,988	234,668
Accrued professional services	430,088	367,072
Other	314,134	299,931
Total accrued liabilities	3,283,942	3,730,616
Less: Long term accrued liabilities	(641,461)	(535,369)
Total current accrued liabilities	$ 2,642,481	$ 3,195,247

Long-Term Debt and Credit Facilities (Details Narrative) - USD ($)	Apr. 26, 2018	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Contractual principal maturities of debt
Total liquidity		14,100,000
Cash and cash equivalents		10,796,072	$ 3,686,302
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000	5,000,000
Line of credit extended date, description	On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to April 25, 2019.
Liquidity ratio	greater than 1.75:1.00
Minimum unrestricted cash balance		1,500,000
Line of credit, outstanding
Line of credit facility, current borrowing capacity		$ 3,300,000
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate	4.50%
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Non-Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate	1.50%

Lease Obligations (Details Narrative) - USD ($)	12 Months Ended
Lease Obligations (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Operating Leased Assets [Line Items]
Rent expense	$ 718,736	$ 588,197
Sublease income	$ 837,949	$ 812,660
January 10, 2019 [Member]
Operating Leased Assets [Line Items]
Lease renewal term	3 years

Lease Obligations - Schedule of Future Minimum Lease Payments Under Non-cancelable Leases (Details)	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 2,334,382
2020	2,364,408
2021	2,404,565
Total minimum lease payments	$ 7,103,355

Convertible Preferred Stock and Stockholders' Equity (Details Narrative)	1 Months Ended		12 Months Ended
	Sep. 30, 2016 $ / shares shares	Jun. 30, 2014 USD ($) shares	Dec. 31, 2018 USD ($) Integer $ / shares shares	Dec. 31, 2017 USD ($) shares	Mar. 05, 2018 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stockholders votes \| Integer			1
Dividends declared \| $
Dividends paid \| $
Exercise price of warrants \| $ / shares			$ 0.70
Warrants exercisable date			Sep. 29, 2021
Increased in stockholders' equity \| $			$ 27,000,000
Increased in common shares outstanding			35,791,927
Proceeds from warrant exercise \| $			$ 9,864,697
Options and stock appreciation rights outstanding			1,165,086	413,301
Number of shares, exercised			2,916
Total compensation cost not yet recognized \| $			$ 600,000
Weighted average amortization period of total compensation cost not yet recognized			4 years
Remaining shares available for issuance			53,465,467	92,322,345
Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual life			8 years 2 months 5 days
Options and stock appreciation rights outstanding			1,165,086
Vested and exercisable			291,679
Vested and exercisable, weighted average exercise price \| $ / shares			$ 7.83
Vested and exercisable, weighted average remaining term			5 years 1 month 27 days
Intrinsic value, outstanding \| $			$ 300,000
Share price \| $ / shares			$ 1.08
Number of shares, vested
Weighted average grant date fair value \| $ / shares			$ 0.76
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock plan expiration date			Mar. 25, 2012
2012 Stock Incentive Plan [Member] \| New Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			2 years
2012 Stock Incentive Plan [Member] \| Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term			10 years
Exercise price as percentage of fair value			100.00%
Options vesting percentage			25.00%
Options vesting period			3 years
2012 Stock Incentive Plan [Member] \| Stock Option [Member] \| Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term			10 years
Exercise price as percentage of fair value			100.00%
2012 Stock Incentive Plan [Member] \| Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term			10 years
Options vesting percentage			25.00%
Options vesting period			3 years
2012 Stock Incentive Plan [Member] \| Time-Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			3 years
2012 Stock Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			4 years
Intrinsic value, outstanding \| $			$ 700,000
Share price \| $ / shares			$ 1.08
Intrinsic value, vested \| $			$ 300,000
2012 Stock Incentive Plan [Member] \| Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, exercised
Proceeds from stock options exercised \| $
2009 Employee Stock Purchase Plan ("ESPP") [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares authorized for issuance		250,000
Eligible employees term		3 months
Maximum purchase percentage of employees compensation		15.00%
Maximum fair value of shares subject to repurchase obligation \| $		$ 25,000
Maximum fair value percentage of shares subject to repurchase obligation		95.00%
Remaining shares available for issuance		51,251
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted warrants exercise			35,791,927
Proceeds from warrant exercise \| $			$ 10,000,000
Remaining shares available for issuance			1,131,151	38,779,119
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / shares					$ 0.70
Maximum [Member] \| 2012 Stock Incentive Plan [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			5 years
Maximum [Member] \| 2012 Stock Incentive Plan [Member] \| Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value, exercised \| $			$ 100,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / shares					$ 0.28
Minimum [Member] \| 2012 Stock Incentive Plan [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			1 year
Series A Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of preferred stock issued	24,000
Preferred stock, par value \| $ / shares	$ 0.001
Preferred stock, stated value \| $ / shares	1,000
Preferred stock, conversion price \| $ / shares	$ 0.65
Common stock issuable from warrants	36,923,078
Preferred stock dividend rate	6.00%
Preferred stock redemption, triggering event, percent of common stock sold threshold	50.00%

Convertible Preferred Stock and Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details) - shares	Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Reserved shares of common stock	53,465,467	92,322,345
Stock Award Plans [Member]
Class of Stock [Line Items]
Reserved shares of common stock	4,438,503	5,573,046
Employee Stock Purchase Plan ("ESPP") [Member]
Class of Stock [Line Items]
Reserved shares of common stock	51,251	125,618
Series A Convertible Preferred Stock Series [Member]
Class of Stock [Line Items]
Reserved shares of common stock	47,844,562	47,844,562
Warrant [Member]
Class of Stock [Line Items]
Reserved shares of common stock	1,131,151	38,779,119

Convertible Preferred Stock and Stockholders' Equity - Summary of Option and Stock Appreciation Rights Activity (Details)	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options/SARs, Outstanding, Beginning Balance \| shares	413,301
Number of Options/SARs, Granted \| shares	950,500
Number of Options/SARs, Exercised \| shares	(2,916)
Number of Options/SARs, Forfeited \| shares	(195,799)
Number of Options/SARs, Outstanding, Ending Balance \| shares	1,165,086
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance	$ 9.04
Weighted Average Exercise Price per Share, Granted	0.76
Weighted Average Exercise Price per Share, Exercised	0.62
Weighted Average Exercise Price per Share, Forfeited	7.66
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	2.54
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	54.90
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	1.07
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Upper Limit	0.62
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	54.90
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	$ 43.90

Convertible Preferred Stock and Stockholders' Equity - Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding	1,165,086	413,301
Weighted Average Exercise Price	$ 2.54	$ 9.04
Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding	1,165,086
Weighted Average Remaining Life	8 years 2 months 5 days
Weighted Average Exercise Price	$ 2.54
Number of Options Currently Exercisable	291,679
Weighted Average Exercise Price per Vested Share	$ 7.83
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.00
Range of Exercise Price, Upper Limit	$ 1.00
Options Outstanding	818,500
Weighted Average Remaining Life	9 years 2 months 5 days
Weighted Average Exercise Price	$ 0.75
Number of Options Currently Exercisable
Weighted Average Exercise Price per Vested Share
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	1.01
Range of Exercise Price, Upper Limit	$ 2.00
Options Outstanding	101,500
Weighted Average Remaining Life	7 years 10 months 10 days
Weighted Average Exercise Price	$ 1.48
Number of Options Currently Exercisable	51,718
Weighted Average Exercise Price per Vested Share	$ 1.86
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	2.01
Range of Exercise Price, Upper Limit	$ 4.00
Options Outstanding	115,791
Weighted Average Remaining Life	6 years 1 month 9 days
Weighted Average Exercise Price	$ 2.15
Number of Options Currently Exercisable	110,666
Weighted Average Exercise Price per Vested Share	$ 2.15
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	4.01
Range of Exercise Price, Upper Limit	$ 10.00
Options Outstanding	86,500
Weighted Average Remaining Life	5 years 2 months 27 days
Weighted Average Exercise Price	$ 4.04
Number of Options Currently Exercisable	86,500
Weighted Average Exercise Price per Vested Share	$ 4.04
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	10.01
Range of Exercise Price, Upper Limit	$ 20.00
Options Outstanding
Weighted Average Exercise Price
Number of Options Currently Exercisable
Weighted Average Exercise Price per Vested Share	$ 0.00
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	30.01
Range of Exercise Price, Upper Limit	$ 40.00
Options Outstanding	30,545
Weighted Average Remaining Life	1 year 11 months 1 day
Weighted Average Exercise Price	$ 34.74
Number of Options Currently Exercisable	30,545
Weighted Average Exercise Price per Vested Share	$ 34.74
Stock Options and Stock Appreciation Rights (SARs) [Member] \| Range of Exercise Prices Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	40.01
Range of Exercise Price, Upper Limit	$ 50.00
Options Outstanding	12,250
Weighted Average Remaining Life	5 months 9 days
Weighted Average Exercise Price	$ 43.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 43.90

Convertible Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2017 \| shares	680,363
Number of Restricted Stock Units, Granted \| shares	422,167
Number of Restricted Stock Units, Vested \| shares	(385,606)
Number of Restricted Stock Units, Forfeited \| shares	(69,275)
Number of Restricted Stock Units, Outstanding, December 31, 2018 \| shares	647,649
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2017 \| $ / shares	$ 1.11
Weighted Average Grant Date Fair Value per Unit, Granted \| $ / shares	0.80
Weighted Average Grant Date Fair Value per Unit, Vested \| $ / shares	1.24
Weighted Average Grant Date Fair Value per Unit, Forfeited \| $ / shares	1.12
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2018 \| $ / shares	$ 0.83

Fair Value Measurements (Details Narrative) - Exchange Warrants [Member] - $ / shares	1 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Warrant expiration date, description		November 2018
Closing stock price	$ 1.21		$ 0.80
Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	70.17%		70.56%
Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	2.19%		1.76%

Fair Value Measurements - Schedule of Assets And Liabilities Measured at Fair Value on Recurring Basis By Level (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Warrants issued		$ 19,574,977
Fair Value, Inputs, Level 1 [Member]
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Total liabilities at fair value		19,574,977
Fair Value, Measurements, Recurring [Member]
Total liabilities at fair value		19,574,977
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member]
Warrants issued		5,746
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member] \| Fair Value, Inputs, Level 1 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member] \| Fair Value, Inputs, Level 2 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member] \| Fair Value, Inputs, Level 3 [Member]
Warrants issued		5,746
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member]
Warrants issued		19,569,231
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member] \| Fair Value, Inputs, Level 1 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member] \| Fair Value, Inputs, Level 2 [Member]
Warrants issued
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member] \| Fair Value, Inputs, Level 3 [Member]
Warrants issued		$ 19,569,231

Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Liabilities (Details)	12 Months Ended
	Dec. 31, 2018 USD ($)
Balance at beginning of period	$ 19,574,977
Issues
Settlements	(16,984,616)
Revaluation	(2,590,361)
Balance at end of period
Fair Value, Measurements, Recurring [Member] \| Warrants Issued August 2013 [Member]
Balance at beginning of period	5,746
Issues
Settlements
Revaluation	(5,746)
Balance at end of period
Fair Value, Measurements, Recurring [Member] \| Warrants Issued September 2016 [Member]
Balance at beginning of period	19,569,231
Issues
Settlements	(16,984,616)
Revaluation	(2,584,615)
Balance at end of period

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
U.S. statutory income tax rate	21.00%	34.00%
Operating loss carryforwards	$ 100,300,000
Net operating loss carryovers expiring unused	92,000,000
Reserves for uncertain tax positions	100,000	$ 100,000
Accrued interest and penalties	100,000
Federal [Member]
Net operating loss carryovers expiring unused	$ 284,700,000
Federal [Member] \| Minimum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2030
Federal [Member] \| Maximum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2037
State [Member]
Net operating loss carryovers expiring unused	$ 1,900,000
Number of prior years subject to examination	10 years
State [Member] \| Minimum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2018
State [Member] \| Maximum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2037

Income Taxes - Schedule of Provision For Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Deferred: Federal	$ (236,779)	$ 13,308,196
Deferred: State and local	(238,946)	(263,860)
Total deferred income tax expense (benefit)	(475,725)	13,044,336
Valuation allowance	475,725	(13,044,336)
Income tax benefit

Income Taxes - Schedule of Reconciliation of Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21.00%	34.00%
State and local taxes, net of federal tax benefit	(42.80%)	1.80%
Permanent differences between book and tax	(390.50%)	(1.50%)
Deferred tax adjustments	293.50%	(6.10%)
Tax cuts & jobs act	0.00%	(244.90%)
State rate adjustments	(292.90%)	(4.00%)
Prior year return-to-provision adjustment	4.30%	0.00%
Valuation allowance	407.40%	220.70%
Effective income tax rate	0.00%	0.00%

Income Taxes - Schedule of Components of Deferred Tax Asset (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Current accruals	$ 1,746,094	$ 1,718,808
Deferred revenue	605	30,648
Depreciation and amortization	1,279,973	1,311,718
Deferred compensation	471,143	633,303
Net operating loss carryovers	22,933,668	22,359,693
Deferred tax assets	26,431,483	26,054,170
Valuation allowance	(26,359,083)	(25,955,759)
Capitalized compensation costs	(72,400)
Net deferred tax assets before deferred tax liabilities		98,411
Accounting method changes		(98,411)
Net deferred tax assets

Net Loss Per Share - Schedule of Computation of Basic And Diluted Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net loss per share attributable to common stockholders:
Net income (loss)	$ 116,756	$ (5,887,410)
Deemed dividend on convertible preferred stock
Cumulative dividend on convertible preferred stock	(1,434,000)	(1,432,259)
Net loss attributable to common stockholders	$ (1,317,244)	$ (7,319,669)
Weighted average number of common shares and equivalents:	52,082,618	22,614,248
Basic EPS	$ (0.03)	$ (0.32)
Diluted EPS	$ (0.03)	$ (0.32)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Loss Per Share - Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Anti-dilutive common shares excluded from the computation of diluted earnings per share	44,687,540	79,410,284
Options to Purchase Common Stock [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,165,086	413,301
Series A Convertible Preferred Stock and Accumulated Dividends [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	41,743,654	39,537,501
Restricted Stock Units [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	647,649	680,363
Warrant [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,131,151	38,779,119

Employee Benefit Plan (Details Narrative) - USD ($)	12 Months Ended
Employee Benefit Plan (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan [Abstract]
Compensation expense recognized	$ 200,000
Employer match of employee contributions	3.00%	0.00%

Product Warranty Provisions (Details Narrative)	12 Months Ended
Product Warranty Provisions (Details Narrative)	Dec. 31, 2018
Product Warranties Disclosures [Abstract]
Standard product warranty coverage term	1 year

Product Warranty Provisions - Schedule of Accrued Warranty (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Product Warranties Disclosures [Abstract]
Warranty accrual, beginning of the fiscal period	$ 164,365	$ 222,845
Accrual adjustment for product warranty	34,253	32,679
Payments made	(49,154)	(91,159)
Warranty accrual, end of the fiscal period	$ 149,464	$ 164,365

Segment Information - Schedule of Geographic Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total	$ 29,346,617	$ 31,144,100
Operating Segments [Member] \| United States [Member]
Total	18,611,676	18,038,638
Operating Segments [Member] \| International [Member]
Total	$ 10,734,941	$ 13,105,462